Diatrizoic Acid (65%) is a high-osmolality, ionic, iodinated contrast medium used for radiographic imaging. It is a tri-iodinated benzoic acid derivative (sodium and meglumine salts) that provides radiopacity by attenuating X-rays. It is primarily used for intravascular, intra-arterial, and body cavity administration to visualize vascular structures and hollow organs. Its high osmolality (approximately 1500 mOsm/kg) is a key differentiating factor from newer low-osmolality agents.
Adult: Dose is volume and concentration dependent on the procedure and patient size. Typical ranges: IV Urography: 25-50 mL (65%); Angiography: Varies by vessel, e.g., 10-40 mL per injection for aortic studies. Maximum single dose should not exceed 200 mL of the 65% solution.
Note: For intravascular use: Administer by slow IV injection or controlled IV infusion/injection using an angiographic catheter. Warm solution to body temperature to reduce viscosity. Use strict aseptic technique. Observe patient closely during and for at least 30 minutes after injection. Pre-procedure hydration with 0.9% NaCl is recommended. Test injection is NOT a reliable predictor of severe reactions.
Diatrizoic Acid provides radiographic contrast by virtue of its high iodine content (approximately 65% by weight). Iodine atoms have a high atomic number (53), which results in significant attenuation (absorption) of X-ray photons. When injected into blood vessels or body cavities, it creates a density difference between the fluid-filled space and surrounding tissues, making lumens and vascular structures visible on X-ray or fluoroscopy.
Pregnancy: Category D (as per some references). Iodinated contrast crosses the placenta and may depress fetal thyroid function. Use only if absolutely essential for maternal diagnosis, after careful risk-benefit assessment. Informed consent required.
Driving: May cause dizziness or vasovagal reactions. Patients should be advised not to drive or operate machinery until any such effects have completely resolved, typically for 12-24 hours post-procedure.
| Metformin | Increased risk of lactic acidosis if contrast-induced nephropathy occurs. Must withhold metformin before and after procedure. | Major |
| Interleukin-2 | Increased risk of delayed adverse reactions to contrast media. | Moderate |
| Beta-blockers (e.g., Propranolol) | May impair response to treatment of anaphylactoid reactions (refractory bradycardia, bronchospasm). | Moderate |
| Nephrotoxic drugs (Aminoglycosides, NSAIDs, Amphotericin B) | Additive risk of acute kidney injury. | Major |
| Diuretics (especially Loop Diuretics) | May exacerbate dehydration and increase risk of nephrotoxicity. | Moderate |
Same composition (Diatrizoic Acid (65%)), different brands: